% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Nelson:294365,
      author       = {B. H. Nelson and P. T. Hamilton and M. T. Phung and K.
                      Milne and B. Harris and S. Thornton and D. L. Stevens and S.
                      Kalaria and K. Singh and C. M. Laumont and E. Moss and A.
                      Alimujiang and N. S. Meagher and A. Bolithon and S. Fereday
                      and C. J. Kennedy and J. Hendley and D. Ariyaratne and K.
                      Alsop and N. Traficante and E. L. Goode and A. N. Karnezis
                      and H. Shen and J. Richardson and C. McKinnon Deurloo and A.
                      Chase and B. Grout and J. A. Doherty and H. R. Harris and K.
                      L. Cushing-Haugen and M. S. Anglesio and K. Heinze and D.
                      Huntsman and A. Talhouk and G. E. Hanley and J. Alsop and M.
                      Jimenez-Linan and P. D. Pharoah and J. Boros and A. H. Brand
                      and P. R. Harnett and R. Sharma and J. L. Hecht and N.
                      Sasamoto and K. L. Terry and B. Y. Karlan and J. Lester and
                      M. E. Carney and M. T. Goodman and B. Y. Hernandez and L. R.
                      Wilkens and S. Behrens$^*$ and R. Turzanski Fortner$^*$ and
                      P. A. Fasching and C. Bisinotto and F. J. Candido Dos Reis
                      and P. Ghatage and M. Köbel and E. Elishaev and F. Modugno
                      and L. S. Cook and N. D. Le and A. Gentry-Maharaj and U.
                      Menon and M. J. García and C. Rodriguez-Antona and K. M.
                      Farrington and L. E. Kelemen and S. Kommoss and A. Staebler
                      and D. W. Garsed and J. D. Brenton and A. M. Piskorz and D.
                      D. Bowtell and A. DeFazio and S. J. Ramus and M. C. Pike and
                      C. L. Pearce},
      title        = {{I}mmunological and molecular features of the tumor
                      microenvironment of long-term survivors of ovarian cancer.},
      journal      = {The journal of clinical investigation},
      volume       = {134},
      number       = {24},
      issn         = {0021-9738},
      address      = {Ann Arbor, Mich.},
      publisher    = {ASCJ},
      reportid     = {DKFZ-2024-02198},
      pages        = {e179501},
      year         = {2024},
      note         = {2024 Oct 29;134(24):e179501},
      abstract     = {Despite an overall poor prognosis, about $15\%$ of patients
                      with advanced-stage tubo-ovarian high-grade serous carcinoma
                      (HGSC) survive ten or more years after standard treatment.We
                      evaluated the tumor microenvironment of this exceptional,
                      understudied group using a large international cohort
                      enriched for long-term survivors (LTS; 10+ years; n = 374)
                      compared to medium-term (MTS; 5-7.99 years; n = 433) and
                      short-term survivors (STS; 2-4.99 years; n = 416). Primary
                      tumor samples were immunostained and scored for
                      intra-epithelial and intra-stromal densities of 10
                      immune-cell subsets (including T cells, B cells, plasma
                      cells, myeloid cells, PD-1+ cells, and PD-L1+ cells) and
                      epithelial content.Positive associations with LTS compared
                      to STS were seen for 9/10 immune-cell subsets. In
                      particular, the combination of intra-epithelial CD8+ T cells
                      and intra-stromal B cells showed near five-fold increased
                      odds of LTS compared to STS. All of these associations were
                      stronger in tumors with high epithelial content and/or the
                      C4/Differentiated molecular subtype, despite immune-cell
                      densities generally being higher in tumors with low
                      epithelial content and/or the C2/Immunoreactive molecular
                      subtype.The tumor microenvironment of HGSC long-term
                      survivors is distinguished by the intersection of T and B
                      cell co-infiltration, high epithelial content and
                      C4/Differentiated molecular subtype, features which may
                      inspire new approaches to immunotherapy.Ovarian Cancer
                      Research Program (OCRP) of the Congressionally Directed
                      Medical Research Program (CDMRP), U.S. Department of Defense
                      (DOD); American Cancer Society; BC Cancer Foundation;
                      Canada's Networks of Centres of Excellence; Canadian Cancer
                      Society; Canadian Institutes of Health Research; Cancer
                      Councils of New South Wales, Victoria, Queensland, South
                      Australia and Tasmania, Cancer Foundation of Western
                      Australia; Cancer Institute NSW; Cancer Research UK;
                      Deutsche Forschungsgesellschaft; ELAN Funds of the
                      University of Erlangen-Nuremberg; Fred C. and Katherine B.
                      Andersen Foundation; Genome BC; German Cancer Research
                      Center; German Federal Ministry of Education and Research,
                      Programme of Clinical Biomedical Research; Instituto de
                      Salud Carlos III; Mayo Foundation; Minnesota Ovarian Cancer
                      Alliance; Ministerio de Economía y Competitividad; MRC;
                      National Center for Advancing Translational Sciences;
                      National Health and Medical Research Council of Australia
                      (NHMRC); Ovarian Cancer Australia; Peter MacCallum
                      Foundation; Sydney West Translational Cancer Research
                      Centre; Terry Fox Research Institute; The Eve Appeal (The
                      Oak Foundation); UK National Institute for Health Research
                      Biomedical Research Centres at the University of Cambridge;
                      University of Pittsburgh School of Medicine; U.S. National
                      Cancer Institute of the National Institutes of Health; VGH
                      $\&$ UBC Hospital Foundation; Victorian Cancer Agency.},
      keywords     = {Cancer (Other) / Cellular immune response (Other) /
                      Epidemiology (Other) / Immunology (Other) / Oncology
                      (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39470729},
      doi          = {10.1172/JCI179501},
      url          = {https://inrepo02.dkfz.de/record/294365},
}